Drug news

NICE now recommends Afinitor (everolimus) + Aromasin (exemestane) to treat postmenopausal women with HER2-negative hormone-receptor-positive advanced breast cancer - Novartis

Read time: 1 mins

Last updated:28th Jun 2017

Published:12th Nov 2016

Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) now recommends Afinitor (everolimus) as a combination treatment with Aromasin (exemestane) for the treatment of postmenopausal women with HER2-negative hormone-receptor-positive advanced breast cancer - the most common form of breast cancer. An oral treatment, Afinitor is restricted to patients whose breast cancer has returned or progressed after initial treatment with hormone therapy and have no signs of the cancer spreading to other organs.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Positive data for V116, an investigational, 21-valent pneumococcal conjugate vaccine specifically designed for adults

Merck Inc., known as MSD outside of the United States and Canada, announced results from STRIDE-10, a Phase III trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain

3 mins

Drug news

Stenoparib shows clear clinical benefit and achieves significant milestone with early conclusion of phase II trial in advanced ovarian cancer

Allarity Therapeutics, Inc. announced the early discontinuation of its Phase II clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer

2 min

Drug news

Calquence (acalabrutinib)combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL)

2 min

See all news